Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects ages 6 to 21 who have loss of smell (anosmia) or dysosmia (disordered smell perception) and thought to have occurred due to COVID-19.~* Subjects who are able to complete the smell test (UPSIT), self-report their loss of smell, and do the assigned daily therapy.~Exclusion Criteria:~* Duration of anosmia or dysosmia \<60 days~* Previous smell retraining~* Prior interventions for loss of smell (excluding those on Flonase and Azelastine)~* Contraindications for nasal budesonide treatment, as determined by the treating physician~* Active cigarette smoker or use of vapes~* Previous head trauma~* Congenital anosmia~* History of brain tumor~* Neurocognitive disorders~* Multiple sclerosis~* Seizure disorder~* Cystic fibrosis~* Primary Ciliary Dyskinesia~* History of nasal polyps~* Inability to self-report

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Smell Retraining Only (Type: ACTIVE_COMPARATOR): Participants will undergo smell retraining for 8 weeks. Each week, participants will choose 4 scents. They will smell each item for 15 seconds very close to the nose once a day.
- Smell Retraining + Budesonide (Type: EXPERIMENTAL): Participants will undergo smell retraining as described above. They will also complete budesonide irrigations once a day by pouring 0.5mg/2ml of budesonide into a irrigation bottle with saline and irrigating the nose.

Based on this trial design, predict the completion outcome and termination type (if applicable).